Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis
Journal article published in 2015 by
Mayenaaz Sidhu,
T. Mersaides,
Elizabeth Liniker,
David J. Tate,
Adnan Nagrial,
Georgina Long,
Neomal S. Sandanayake,
Viraj C. Kariyawasam,
N. Sandanyake,
Richard Kefford 
,
Matteo S. Carlino ,
Vu Kwan
,
Matteo S. Carlino ,
Vu Kwan
